AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc.

Abcellera Biologics, Inc. (($ABCL)) has held its Q2 earnings call. Read on for the main highlights of the call. AbCellera’s latest earnings call st...

AbCellera Earnings Call Balances Cash Strength With Risk

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on AbCellera Biologics, with a price target of $12.00. Bratz...

Piper Sandler Remains a Buy on AbCellera Biologics (ABCL)

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on AbCellera Biologics today and set a price target of $9.00. According to TipRanks,...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABCL	$11.43	-1.21%	2.00M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABCL	$11.43	-1.2%	2.00M
3
4
5
6

ABCL

Get AbCellera Biologics Inc. Data in Excel

Get AbCellera Biologics Inc. Data in Excel